-2-1.png){kind=logo}
06 · The landscape
Where is this legal, and where is it heading?
Written mainly for clinicians and referral partners assessing whether a program is legitimate, and for anyone who wants to understand the legal context.
Two facts matter more than any other. Psilocybin is not approved by the U.S. Food and Drug Administration for any medical indication yet. And Beckley programs operate only in Jamaica and the Netherlands, jurisdictions where the relevant use is permitted. They are not offered in the United States.1
Beyond those two points, regulatory status varies considerably between jurisdictions and continues to change. For the specifics in any jurisdiction, we direct clinicians and referral partners to qualified legal counsel.2
How this research relates to a Beckley retreat
The studies described here were run as clinical trials, in hospitals or research settings, using standardized synthetic compounds under medical supervision. Beckley is not a clinical program. Our retreats are non-clinical wellbeing experiences that use natural psilocybin and are built around preparation, a guided experience, and integration.
What we can state today
Deliberately limited to what is unambiguous. Regulatory status varies by jurisdiction and changes over time.
Regulatory status
Psilocybin is not approved by the U.S. Food and Drug Administration for any medical indication yet, and nothing on this site should be read as suggesting otherwise.
Where we operate
Beckley programs run in Jamaica and the Netherlands only, and are not offered in the United States.
Why this page is deliberately short
Regulatory information is the easiest content on a site like this to get wrong, and the most consequential when it is wrong. Rules differ between countries and between states or provinces within them, they change, and a summary written for general readers can easily be mistaken for legal guidance.2
So this page states only what is unambiguous. For the position in any jurisdiction where we operate, and how referral partners should think about it, we direct you to Beckley Retreats and to qualified legal counsel.
For clinicians and referral partners
If you are assessing whether to refer someone, the questions worth asking any provider are: where does the program legally operate, what is excluded at screening, what qualifications do facilitators hold and in what capacity do they act, and what happens if something goes wrong. Our answers to the first three are set out on the safety page.3
What this page does not do
The boundaries here are firm.
- This is not legal advice. Nothing on this page should be relied on as guidance about the legality of any substance or activity in your jurisdiction.
- It is not an invitation. Nothing here is intended to encourage or facilitate activity that is unlawful where you live.
- It is not a claim of approval. Operating legally in a given jurisdiction is not the same as a substance being medically approved, and we do not conflate the two.
- It is not exhaustive. Regulatory status varies by jurisdiction and changes over time; for specific questions, consult qualified legal counsel in your jurisdiction.
A note on this page
This is the one area of the research hub where we would rather publish less than risk publishing something inaccurate. Regulatory content on this site is reviewed by legal counsel.
References
Every figure and finding stated on this page traces to one of the sources below.
- Beckley Retreats regulatory and jurisdictional statement. Programs operate in Jamaica and the Netherlands and are not offered in the United States. beckleyretreats.com
- Regulatory status for psilocybin varies by jurisdiction and changes over time. For current legal status in any jurisdiction, consult qualified legal counsel.
- See our safety and rigor page for screening criteria and facilitator arrangements. Safety and rigor